相关实验视频

Updated: Jun 22, 2025

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

艾米齐祖马布作为获得性血友病A的第一线治疗

Michael Iarossi¹, Cedric Hermans¹

¹Division of Hematology, Hemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain, Brussels, Belgium.

Research and practice in thrombosis and haemostasis

|July 2, 2024

概括

获得的血友病A (AHA) 治疗可以通过使用埃米齐祖马布来改善. 这种双特异性抗体为当前疗法提供了一个潜在的更安全的替代方案,减少出血风险和免疫抑制治疗的副作用.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
自免疫性疾病自免疫性疾病

背景情况:

获得性血友病A (AHA) 是一种罕见的自身免疫性疾病,其特征是对因子VIII (FVIII) 的自身抗体.
目前的静血疗法,如绕过剂,具有局限性,包括静脉注射和短半衰期.
免疫抑制治疗 (IST) 是至关重要的,但具有重大风险,特别是在患有并发病的老年患者中.

研究的目的:

评估艾米齐祖马布作为一种潜在的第一线治疗获得的血友病A.
探索埃米齐祖马布在减少出血并发症和与IST相关的副作用方面的益处.

主要方法:

审查最近的临床经验和支持埃米齐祖马布在AHA中使用的论据.
与标准绕过剂和IST相比,埃米齐祖马布的疗效和安全概况的比较.

主要成果:

艾米齐祖马布模仿FVIII活性,在先天性血友病中表现出有效性,包括使用抑制剂的病例.
临床经验表明,埃米齐祖马布作为AHA的第一线疗法具有潜力.
这一策略可以减少出血事件,并减轻与IST相关的严重副作用.

结论:

埃米齐祖马布是治疗获得的血友病A的有希望的替代品.
早期启动埃米齐祖马布可以通过减少出血和IST负担来改善患者的结果.
针对艾米齐祖马布治疗的定制治疗可能为AHA患者提供更安全,更有效的方法.

关键词:

获得的血友病A 发生出血,出血.这种疾病是共患的.艾米奇祖马布 (Emicizumab) 是一种药物.免疫抑制疗法是一种免疫抑制疗法.

更多相关视频

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...